Focusing our work on infectious and inflammatory dermatology and cosmetics
SkinDermic® is a clinical-stage biotechnology company focused on developing breakthrough and innovative first-in-class small molecule drugs for the treatment of infectious and inflammatory skin diseases.
SkinDermic® has developed novel, safer and highly effective first-in-class drug candidates, internally discovered, for the treatment of acne, Kaposi’s Sarcoma and other HHV8 associated diseases.
SkinDermic SkinDermic® as completed Phase-1/2 (proof of concept) clinical trials of its First-in-Class treatments for acne and Kaposi’s sarcoma.
In parallel, SkinDermic® also develops, using its own advanced research programs, biotechnology-derived first-in-class ingredients for use as dermo-cosmetics.
SkinDermic’s business strategy is to partner its proprietary drug candidates.